SG Americas Securities LLC Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX

SG Americas Securities LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 560.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 61,375 shares of the biopharmaceutical company’s stock after acquiring an additional 52,086 shares during the period. SG Americas Securities LLC’s holdings in TG Therapeutics were worth $2,217,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. HB Wealth Management LLC bought a new stake in shares of TG Therapeutics in the third quarter worth about $216,000. Signature Wealth Management Partners LLC increased its stake in TG Therapeutics by 3.7% in the 3rd quarter. Signature Wealth Management Partners LLC now owns 11,180 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 400 shares during the last quarter. Daymark Wealth Partners LLC raised its holdings in shares of TG Therapeutics by 8.8% during the 3rd quarter. Daymark Wealth Partners LLC now owns 49,500 shares of the biopharmaceutical company’s stock worth $1,788,000 after acquiring an additional 4,000 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of TG Therapeutics by 8.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 186,711 shares of the biopharmaceutical company’s stock worth $6,745,000 after acquiring an additional 14,408 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new position in shares of TG Therapeutics during the 3rd quarter valued at approximately $34,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $27.87 on Wednesday. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $46.48. The company has a market capitalization of $4.42 billion, a price-to-earnings ratio of 10.03 and a beta of 1.86. The firm’s 50-day moving average is $30.94 and its 200 day moving average is $32.60.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $2.19. The business had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The company’s revenue for the quarter was up 92.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.02 earnings per share. Research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

TGTX has been the topic of several research reports. JPMorgan Chase & Co. boosted their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, December 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright began coverage on TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.25.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This represents a 2.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.64% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.